Core Viewpoint - The article highlights the successful IPO of Jinfang Pharmaceutical Technology (Shanghai) Co., Ltd., marking it as the first biotech company in the Hong Kong IPO phase to hold both a listed new drug and multiple BD (business development) revenue streams [3][5]. Group 1: IPO Details - Jinfang Pharmaceutical officially listed on the Hong Kong Stock Exchange on September 19, 2025, under the stock code "2595" [3]. - The IPO raised a total of $268 million, setting a record for the Hong Kong 18A biotech sector since 2022 [3]. - The cornerstone investment of $100 million also marked a new high for Hong Kong 18A biotech companies since 2022 [3]. Group 2: Company Overview - Founded in 2017, Jinfang focuses on innovative and effective treatment solutions for oncology, autoimmune, and inflammatory diseases, targeting unverified innovative targets and indications with global intellectual property rights [6]. - The company has established a comprehensive and differentiated RAS product matrix, with eight candidate drugs, five of which are in clinical stages, addressing treatment needs for various advanced solid tumors [6]. Group 3: Key Products - The core product GFH925 (Fluorazepine Tablets) is the first KRAS-targeted drug approved in China for treating KRAS G12C mutation non-small cell lung cancer (NSCLC) [6]. - GFH375 (oral KRAS G12D inhibitor) shows promising treatment potential for advanced solid tumors, with ongoing clinical trials and FDA fast track designation for specific indications [7][8]. Group 4: Strategic Partnerships and Revenue - Jinfang has recorded revenue through external collaborations, including a domestic licensing agreement with Innovent Biologics for GFH925 in 2021 [8]. - The company has also secured overseas licensing agreements for GFH009 and GFH375, indicating a robust business development strategy [8]. Group 5: Investor Support - Notable investors include Dinghui Investment and Huagai Capital, both holding over 5% of the company’s shares prior to the IPO [9][10]. - Investors express confidence in Jinfang's potential for sustainable growth and its ability to create value for shareholders and society [10][12].

Group 1: Hesai Group (禾赛) - Hesai Group plans to officially list in Hong Kong on September 16 with the stock code "2525", becoming the first global lidar company to list in Hong Kong [3] - The company has attracted six cornerstone investors, raising a total of $148 million (approximately HKD 1.15 billion), with notable contributions from existing shareholders [3] - In Q2, Hesai delivered a total of 352,095 lidar units, representing a year-on-year growth of 306.9%, with ADAS product deliveries at 303,564 units, up 275.8% [4] - For the first half of the year, total lidar deliveries reached 547,913 units, a 276.2% increase year-on-year, surpassing the full-year target for 2024 [4] - Hesai's revenue for Q2 was RMB 710 million, a growth of over 50% year-on-year, with a net profit exceeding RMB 40 million, significantly surpassing profitability targets [5] Group 2: Genfleet Therapeutics (劲方医药) - Genfleet Therapeutics plans to list in Hong Kong on September 19 under the stock code "2595.HK", with cornerstone investors committing a total of $100 million (approximately HKD 780 million) [7] - The company focuses on developing new treatment options for tumors, autoimmune, and inflammatory diseases, with eight candidate drugs in its pipeline, five of which are in clinical stages [7] - The core product GFH925 has shown a 49.1% objective response rate in key clinical trials and is set to be commercialized in collaboration with a partner [8] Group 3: Chery Automobile (奇瑞) - Chery has passed the Hong Kong Stock Exchange hearing and is recognized as the second-largest independent passenger car brand in China and the eleventh largest globally [10] - The company is projected to sell over 2.295 million vehicles globally in 2024, with a year-on-year growth exceeding 25% across various markets [10][11] - Financially, Chery's revenue is expected to grow from RMB 926.18 billion in 2022 to RMB 2,698.97 billion in 2024, with net profits increasing from RMB 58.06 billion to RMB 143.34 billion in the same period [12] Group 4: BeBeBus - BeBeBus, a high-end parenting product brand, has passed the Hong Kong Stock Exchange hearing and is set to list soon [14] - The company ranks first in the durable parenting products market for mid-to-high-end consumers in China, with a significant average transaction amount [14][15] - Financial performance shows revenue growth from RMB 5.07 billion in 2022 to RMB 12.49 billion in 2024, with a gross margin maintained above 49% [15][16]

Core Viewpoint - Genfleet Therapeutics is set to conduct an IPO from September 11 to 16, aiming to raise approximately HKD 15.82 billion, with a net amount of HKD 14.43 billion from the issuance of 77.6 million H-shares priced at HKD 20.39 each [2]. Group 1 - The company has secured cornerstone investments from several prominent institutions, totaling USD 100 million (approximately HKD 780 million), which accounts for about 49% of the total shares offered [2]. - Genfleet Therapeutics focuses on developing novel therapies for tumors, autoimmune, and inflammatory diseases, with a pipeline that includes eight candidate drugs, five of which are in clinical stages [2]. Group 2 - The core product GFH925 (Fluorouracil Tablets, marketed as "Dabert") is the first KRAS G12C inhibitor approved in China and the third globally, having received approval from the National Medical Products Administration in August 2024 for treating non-small cell lung cancer (NSCLC) [3]. - GFH925 demonstrated a 49.1% objective response rate and a 90.5% disease control rate in key clinical trials, showcasing significant clinical advantages [3]. - The product is being commercialized in collaboration with Innovent Biologics (1801.HK), and efforts are underway to advance market access [3]. Group 3 - The company is also advancing the overseas clinical development of GFH925, with a completed Phase Ib trial in the EMA regulatory region, testing its combination with cetuximab as a first-line treatment for advanced NSCLC [4]. - The Phase II portion of this trial is expected to be completed by Q4 2025, with the potential for synergistic effects in inhibiting the EGFR-RAS pathway [4]. - Another core product, GFH375, an oral KRAS G12D inhibitor, is currently undergoing Phase II clinical trials in China, and Genfleet has entered into a licensing agreement with Verastem (VSTM.US) for three candidate products, including GFH375, for development and commercialization outside Greater China [4]. Group 4 - The funds raised from the IPO will primarily be used to advance the global clinical development of core products, expand the product pipeline, enhance CMC capabilities, and supplement working capital [4].